NASDAQ$COGT
Cogent Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Cogent Biosciences reported its first quarter 2025 financial results, highlighting progress in clinical trials and a strong cash position.
Cogent Biosciences reported a net loss of $72.0 million for the first quarter of 2025, an increase from $58.3 million in the same period last year. The company ended the quarter with $245.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2026, including key clinical trial readouts.
- Net loss for Q1 2025 was $72.0 million, compared to $58.3 million for Q1 2024.
- Cash, cash equivalents, and marketable securities totaled $245.7 million as of March 31, 2025.
- Research and development expenses increased to $63.0 million in Q1 2025 from $52.7 million in Q1 2024, driven by ongoing clinical trials.
- General and administrative expenses rose to $11.9 million in Q1 2025 from $9.7 million in Q1 2024 due to organizational growth.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$0
Forward guidance
Cogent Biosciences anticipates significant clinical trial readouts in 2025 and expects its current cash reserves to fund operations into late 2026, supporting a potential launch of bezuclastinib in 2026.
Tailwinds
- SUMMIT top-line results in NonAdvanced SM expected in July 2025.
- APEX top-line results in Advanced SM expected in the second half of 2025.
- PEAK top-line results in GIST expected by end of 2025.
- Sufficient cash to fund operations into late 2026, including through clinical readouts.
- Potential commercial launch of bezuclastinib in 2026.
Headwinds
- Forward-looking statements are subject to risks and uncertainties, and actual results may differ.
- No guarantee that forecasts or milestones will be achieved.
- New risks and uncertainties may emerge over time.
- The company does not undertake to publicly update or revise forward-looking statements.
- Reliance on forward-looking statements should be limited to the date they were made.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro